Artemis Investment Management LLP Buys 48,253 Shares of Becton Dickinson and Co (BDX)
Artemis Investment Management LLP lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 2,601.2% during the 3rd quarter, Holdings Channel reports. The firm owned 50,108 shares of the medical instruments supplier’s stock after purchasing an additional 48,253 shares during the quarter. Artemis Investment Management LLP’s holdings in Becton Dickinson and were worth $13,073,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of BDX. Acropolis Investment Management LLC acquired a new position in Becton Dickinson and in the third quarter valued at approximately $101,000. Almanack Investment Partners LLC. acquired a new position in Becton Dickinson and in the second quarter valued at approximately $105,000. Truvestments Capital LLC acquired a new position in Becton Dickinson and in the third quarter valued at approximately $105,000. Bartlett & Co. LLC lifted its holdings in Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 435 shares during the last quarter. Finally, Bridgeworth LLC acquired a new position in Becton Dickinson and in the second quarter valued at approximately $131,000. Institutional investors and hedge funds own 86.25% of the company’s stock.
A number of research firms recently commented on BDX. Citigroup upped their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Barclays set a $260.00 price objective on Becton Dickinson and and gave the company a “hold” rating in a report on Thursday, November 8th. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Piper Jaffray Companies decreased their price objective on Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, November 6th. Finally, Morgan Stanley upped their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $253.79.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.93. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.40 earnings per share. Analysts predict that Becton Dickinson and Co will post 12.1 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Shareholders of record on Monday, December 10th will be given a $0.77 dividend. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend is Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a yield of 1.27%. Becton Dickinson and’s payout ratio is presently 27.25%.
In other Becton Dickinson and news, insider Thomas E. Polen, Jr. sold 5,243 shares of the business’s stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $243.86, for a total value of $1,278,557.98. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy M. Ring sold 42,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. In the last three months, insiders sold 75,908 shares of company stock worth $18,085,616. 1.00% of the stock is owned by corporate insiders.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Read More: Depreciation
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.